Evidence map›Paper›PMID 36276464›Full record

Article3 Biotech2022

Comparative heating efficiency and cytotoxicity of magnetic silica nanoparticles for magnetic hyperthermia treatment on human breast cancer cells.

Melek Acar, Kubra Solak, Seyda Yildiz, Yagmur Unver, Ahmet Mavi

Open access · greenAbstract read
In one paragraph

Article in 3 Biotech, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Melek AcarDepartment of Molecular Biology and Genetics, Faculty of Science, Atatürk University, Erzurum, Turkey.ORCID 0000-0001-5931-7799
Kubra SolakDepartment of Nanoscience and Nanoengineering, Graduate School of Natural and Applied Science, Atatürk University, Erzurum, Turkey.ORCID 0000-0001-6643-3368
Seyda YildizDepartment of Molecular Biology and Genetics, Faculty of Science, Atatürk University, Erzurum, Turkey.ORCID 0000-0003-0957-7343
Yagmur UnverDepartment of Molecular Biology and Genetics, Faculty of Science, Atatürk University, Erzurum, Turkey.ORCID 0000-0003-1497-081X
Ahmet MaviDepartment of Nanoscience and Nanoengineering, Graduate School of Natural and Applied Science, Atatürk University, Erzurum, Turkey.ORCID 0000-0003-1207-9783
Atatürk University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Magnetic hyperthermia (MHT) is a promising treatment for a variety of cancers due to its ability to increase the sensitivity of cells to other treatments, such as chemotherapy. Superparamagnetic nanoparticles (MNPs) were used for MHT treatment due to their heat generation ability under an AC magnetic field (AMF). In this study, iron oxide and zinc-doped iron oxide MNPs were produced and modified with silica to obtain eleven different types (MSNP-I to -XI) of magnetic silica nanoparticles (MSNPs). The MSNPs which show the highest heating capacity were selected to investigate their MHT ability on non-tumourigenic MCF-10A and tumourigenic MCF-7 cell lines. The cytotoxicity results indicated that the size, the content of the magnetic core and silica coating thickness were important in the heating capacity of MSNPs under AMF. After MHT treatment, selected MSNPs showed limited cytotoxicity on MCF-10A, but significant cell death on MCF-7. Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-022-03377-y.

Indexed as

Breast cancerIron oxideMagnetic hyperthermiaMagnetic nanoparticlesZinc-doped iron oxide

Identifiers

PMID36276464
PMCPMC9547765
OpenAlexW4303633967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.